NCT04392206View on ClinicalTrials.gov

AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
End Stage Renal Disease
Interventions
DRUG

Adipose Derived Mesenchymal Stem Cells

The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution

Trial Locations (1)

32224

RECRUITING

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

Houssam Farres, M.D.

OTHER